H.C. Wainwright Reiterates a Buy Rating on Vascular Biogenics (VBLT)

By Austin Angelo

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Vascular Biogenics (VBLTResearch Report) today and set a price target of $3. The company’s shares closed yesterday at $1.21.

According to TipRanks.com, Ramakanth has currently no stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 31.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, Gritstone Oncology Inc, and IntelGenx Technologies.

Vascular Biogenics has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $3.10 and a one-year low of $0.60. Currently, Vascular Biogenics has an average volume of 115.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids.